ⓘ Ligelizumab

                                     

ⓘ Ligelizumab

Ligelizumab is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It binds to IGHE an acts as an immunomodulator.

This drug developed by Novartis Pharma AG. In 2018, ligelizumab undergoing phase III clinical trials.

                                     
  • effective in treating allergic rhinitis hay fever and peanut allergy and Ligelizumab a high - affinity TNX - 901 under active clinical development at Novartis